Mitogenic activities on confluent f ibroblasts by sera from patients with scleroderma and normal controls were studied. In experiments using eight different fibroblast strains (one human fetal lung fibroblast, one foreskin fibroblast, three adult skin fibroblast, and three scleroderma fibroblast), pooled scleroderma serum showed lower mitogenic activity by 3 H-thymidine incorporation assay than pooled normal serum. Individual serum investigations revealed that 11 of 33 patients (33%) showed low mitogenic activities; all 11 patients were receiving dipyridamoie. Of 15 patients, 11 (73%) receiving dipyridamoie showed low mitogenic activities; none of 18 patients not receiving dipyridamoie showed low mitogenic activities. Approximately 70% of this serum activity was inhibited by the addition of antl-platelet-derived growth factor (PDGF) antibody indicating that most of this serum activity seemed to be derived from PDGF. Western blot analysis of extracts of normal sera before and after administration of dipyridamoie with antihuman PDGF antibody showed a large decrease in the amount of immunoreactive PDGF present. These data indicate that dipyridamoie is an effective drug to lower release of PDGF during blood clotting.
T he role of platelet-derived growth factors (PDGF) in the pathogenesis of vascular disease has been an active area of research. Several growth-promoting 1 " 4 and chemotactic factors 5 " 8 for connective tissue cells have been shown to be contained in the alpha granules of the platelet. 9 As described in the response to injury hypothesis of Ross, 10 PDGF-like factors from various cell types are released into the vessel wall and recruit the underlying connective tissue to proliferate at the intimal surface forming a fibromuscular lesion. It has been extremely difficult to test the role of platelets in vascular disease processes in vivo. One reason has been the difficulty of neutralizing platelet function in the intact organism without compromising the individual's general blood clotting mechanisms.
Scleroderma represents another vascular disease in which there is a proliferation of connective tissue surrounding the blood vessel. 11 " 13 Previous studies have reported that sera from some scleroderma patients contain elevated levels of mitogenic activity for fibroblastic cells. 14 " 16 For this reason, we measured the levels of fibroblast mitogenic activity in scleroderma patients.-We found many with significantly decreased levels of fibroblast mitogenic activity compared with that of the normal controls. All of the pa-tients with decreased levels of mitogenic activity were being treated with dipyridamoie. This effect was maintained as long as dipyridamoie treatment was continued, but the level of serum mitogenic activity returned to normal after the treatment was terminated. Immunologic tests with specific IgG to human PDGF confirmed that the majority of the mitogenic activity present was PDGF-related and that PDGF levels were decreased in sera collected from individuals receiving dipyridamoie therapy. Thus, dipyridamoie may be useful in preventing the continued aggregation and release reactions of platelets in the treatment of vascular diseases where platelets may play a potential role. Additionally, these data suggest that dipyridamoie treatment could be used to develop an animal model having altered release of platelet factors in order to determine the roles of these factors in normal and pathological states in vivo.
Methods

Sera
Sera from 33 scleroderma patients (23 females, 10 males, mean age 46.9 years, range 26 to 74) at the Medical University of South Carolina were studied. All patients satisfied American Rheumatism Association preliminary clinical criteria. 17 As controls, sera from 16 healthy donors (10 females, 6 males, mean age 36.7 years, range 22 to 59) were also studied. Blood was allowed to clot at room temperature for 1 to 2 hours, was centrifuged at 3000 rpm for 20 minutes, and the sera were stored at -20°C prior to use. After thawing, they were heat-inactivated (56°C for 30 minutes). In some experiments, pools of 4 to 7 different individual sera were used. All procedures had informed consent and institutional approval. 
DIPYRIDAMOLE EFFECT ON SERUM PDGF LEVELS
Growth Assays
Confluent fibroblasts were trypslnized and 4 x 10 4 cells were placed in 16 mm culture plates (Costar, Cambridge, Massachusetts) in DMEM with 10% FCS. Cells were incubated for 4 to 6 days until confluent, and then the medium was changed to DMEM containing test serum (5%, 10%, 20%). After 16 hours, cells were labeled for 2 hours with 2 ftCI/ml of 3 H-thymidine (Amersham, Arlington Heights, Illinois). The cell layers were washed three times with phosphate-buffered saline and five times with ice-cold, 5% trichloroacetic acid, and dissolved in 1 ml of 0.1 N NaOH and 0.1% sodium dodecyl sulfate (Sigma Chemical Company, St. Louis, Missouri). An aliquot of this extract was counted in a Beckman scintillation counter. The background was measured by adding serum-free medium with 2 mg/ml bovine serum albumin.
Antl-Platelet-Derlved Growth Factor Antibody
Purified PDGF was obtained from human platelets as described before. 18 Antibodies to PDGF were prepared in goats using purified human PDGF as an antigen. Goats were immunized with 20 /ig of purified PDGF In Freund's complete adjuvant via multiple Intradermal injections. After 28 days, the goats were rechallenged with 20 ^g of pure PDGF In Freund's incomplete adjuvant. Immune serum was collected 7 days after injection of antigen. The serum used in these experiments was collected from the fourth immunization cycle. Antiserum was tested from anti-PDGF activity by the specific immunoprecipitation of 12S l-labeled PDGF using Staph A cells (Calbiochem, La Jolla, California) as an Immunoabsorbant. The IgG fraction of immune serum was prepared by chromatography on DEAE-Affigel Blue Sepharose (0.02 M NaCI; 0.02 M Tris; pH 8.0) (Biorad, Richmond, California). Anti-PDGF IgG was used in all experiments described. Western blots were performed as described by Towbin et al. 19 using affinity purified rabbit antigoat IgG (alkaline phosphatase conjugated) (Kirkegaard and Perry Laboratories, Incorporated, Gaithersburg, Maryland).
Platelet Extracts
Platelet extracts were obtained by acid-ethanol extraction and ether precipitation. 4 The ether-precipitated pro- teins were redissolved in 1 M acetic acid and stored at -20°C. Samples from 5 x 10 7 platelets were lyophylized, redissolved in 5 mM HCI, and added to culture medium to test mitogenic activities.
Results
Serum Mltogenlc Activity
Initially, we tested pooled normal and scleroderma serum for mitogenic activity using the 3 H-thymldlne incorporation assay described under Methods. Scleroderma serum showed less mitogenic activity on fetal lung fibroblasts (MRC-5) than normal control serum at concentrations of 5%, 10%, and 20% ( Figure 1 ). This lowered mitogenic activity of scleroderma serum was reproduced in all experiments using eight flbroblast strains (see Methods). Data at 10% serum concentration are shown In Table 1 . No significant differences were shown between human sera before or after heat inactivation.
The mitogenic activity of 33 sera from patients with scleroderma and 16 sera from normal controls was measured by 3 H-thymidlne incorporation assay on foreskin fibroblasts after stimulation with 20% serum. As shown in Figure 2, the mean of scleroderma patients' stimulation index (SI 4.0 ± 1.8) was significantly lower than the control group (SI 5.1 ± 1.1) by analysis of Student's f test (p < 0.05). Sera from 11 of 33 scleroderma patients gave responses under the normal range (<mean of normal controls -2 so). Sderoderma patients grouped into a normal mitogen group (n = 22, SI a 2.96) and a low mitogen group (n = 11, SI <2.96) showed no significant differences in age, duration, and frequencies of truncal sclerosis or of involvement of lung, esophagus and kidney. However, when patients with scleroderma were grouped into those receiving dipyridamole and those not taking dipyridamole, all 11 patients who showed serum low mitogenic activity were receiving dipyridamole. Sera from 11 of 15 (73%) dipyridamole-treated patients showed low mitogenic activity, while sera from none of 18 patients not taking dipyridamole showed low mitogenic activity. The mean of the stimulation indexes of the group taking dipyridamole (SI = 2.6) was significantly lower than that of those not receiving dipyridamole (SI = 5.2) and that of normal control group (SI = 5.1) (p < 0.001). Platelet counts measured at the same time when blood was drawn or within 2 months, did not show any significant difference between the group taking dipyridamole (n = 14, 271 ± 102 x 10 4 ) and those Individuals not taking dipyridamole (n = 16, 307 ± 68 x 10 4 ). These findings are similar to those reported by Emmons et al. 20 and Rajah et al. 21 which showed that dipyridamole had no significant effect on the circulating platelet count either during or after therapy. Values are means ± SD.
Serum Mixing Experiments
To determine whether lowered mitogenic activities observed in the sera from scleroderma patients are due to the presence of inhibitors in the sera, either pooled scleroderma serum or pooled normal serum (2%, 5%, 10%) was added to 5% normal serum, and the mitogenic activities in these mixed sera were tested. As shown in Table 2 , the data from these experiments indicate that pooled sclero- Table 3 Values are the means of triplicate wells ± SEM. DP = dipyridamole, PDGF = platelet-derived growth factor. derma serum contains decreased levels of mltogens and does not decrease the level of mitogenlc activity found in normal serum.
. Dipyridamole Effect on 3 H-Thymldlne Incorporation by Foreskin Flbroblasts
Reversibility of the Dipyridamole Effect on Decreased Serum Mitogenlc Activity
In two scleroderma patients, serum mitogenic activities were compared before and after stopping dipyridamole. The sera obtained while the patients were receiving dipyridamole (400 mg/day) showed low mitogenic effects; sera obtained 2 weeks after stopping dipyridamole showed normal mitogenic effect (Figure 3 ). Additionally, in three normal controls, mitogenic activities in the sera were compared before and after taking dipyridamole (300 mg/ day) for 3 days. Dipyridamole reduced the mitogenic effect in the serum by 78%, while it did not reduce mitogenic activities in the platelet extracts.
Evidence that Serum Mltogen Is PDGF-Related
The major mitogenic factor contained in serum for fibroblastic cells is the platelet-derived growth factor. 1 " 3 One means of determining whether the mitogenic activity present in both the low mitogen (dipyridamole-treated patients) sera and normal sera is PDGF-like, is to test the ability of anti-PDGF antibody to neutralize the mitogenic activities contained in these sera. Anti-PDGF antibody (60 /xg/ml) was incubated with DMEM containing 10% test serum for 1 hour before changing media. This concentration of anti-PDGF antibody gave maximal effect of decreasing mitogenic activities. As shown in Figure 4 , anti-PDGF antibody had a slight effect on 3 H-thymidine incorporation by foreskin fibroblasts in medium with 10% FCS, while approximately 70% of 3 H-thymidine incorporation was suppressed in medium with 10% scleroderma or 10% normal serum, suggesting that the major mitogenic activities in both scler-
Dlpyrldamole Effects on Foreskin Flbroblast Cultures
To ensure that the dipyridamole was not altering the growth response of the fibroblast, we tested the effect of dipyridamole on the growth response of fibroblasts to serum and platelet-derived growth factor. The presence of dipyridamole at concentrations comparable to those found In treated patients' sera did not affect 3 H-thymidine incorporation of foreskin fibroblasts In response to serum or PDGF (Table 3 ). These data indicate that dipyridamole lowered the mitogenic activity of the serum for fibroblastic cells by removing some mitogen from the serum and not by directly inhibiting the growth of the fibroblasts. oderma and control serum were derived from PDGF. Fetal calf serum has low levels of PDGF compared to human sera and the antibody used does not appear to cross-react with bovine PDGF. Preimmune IgG had no effect on the mitogenic activity of either normal or scleroderma sera (data not shown). These data indicate that treatment with dipyridamole can lower the level of PDGF present in serum.
-
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To confirm this, we quantitated the level of PDGF present by a Western blot assay using antihuman PDGF IgG. Crude PDGF was prepared by acid-ethanol extraction and ether precipitation from 1 -ml aliquots of serum prepared from a normal control before and after taking dipyridamole. 4 The ether-precipitated proteins were redissolved in I ml of 1 M acetic acid and 200 fi\ was lyophylized and electrophoresed on a 12% acryiamide gel containing SDS under nonreducing condition. The proteins were then electrotransferred to nitrocellulose paper and the PDGF present was detected immunologically. The data shown in Figure 5 indicate that the PDGF level decreased to approximately 75% of normal after administration of dipyridamole. These data support the results of our mitogenic assays which indicate that there is 50% to 80% decrease in PDGF in the sera of individuals treated with dipyridamole.
Discussion
Using a 3 H-thymidine incorporation assay of confluent fibroblast cultures, we found less mitogenic activity in scleroderma serum than in control serum regardless of the source of fibroblasts. This result was confirmed using eight different fibroblast strains (one human fetal lung fibroblast, one foreskin fibroblast, three adult skin fibroblast, three scleroderma fibroblast). Decreased serum mitogenic activity on confluent foreskin fibroblasts was demonstrated in I1 of 33 patients with scleroderma, all of whom were receiving dipyridamole. Approximately 70% of mitogenic activity in all sera tested was blocked by preincubation with anti-PDGF antibody, indicating that most of these mitogenic activities were derived from PDGF-related growth activities. We also observed increases of serum mitogen after stopping dipyridamole in the patients who were taking dipyridamole; we observed decreases of serum mitogen in normal controls after taking dipyridamole. Thus, dipyridamole, a known antiplatelet drug, may block the release of PDGF from platelets, explaining why sera from scleroderma patients taking dipyridamole showed low mitogenc effects.
Antiplatelet drugs have been used for the treatment of patients with scleroderma, because of a vascular hypothesis for its pathogenesis. 11 " 13 Kahaleh et al. 22 reported that elevated levels of circulating platelet aggregates and 13thromboglobulin in the patients with scleroderma and these platelet abnormalities were reduced by treatment with dipyridamole (400 mg/day) and aspirin (150 mg every third day) for 2 to 4 months. However, in a randomized, double-blind, controlled study, 23 no clinical or objective laboratory improvement was noted in the patients who were taking dipyridamole (225 mg/day) and aspirin (975 mg/day). This difference might be due to the use of different dosages of dipyridamole and aspirin, suggesting that further investigation of antiplatelet drugs is necessary. Patient selection may also be important in these studies.
In recent years, the effects of scleroderma serum on fibroblast replication have been reported. 14 " 16 ' 24~26 Some studies 14 " 16 suggested that sera from patients with scleroderma showed elevated levels of mitogenic activity for adult skin fibroblasts, while others 24 " 26 reported lower levels or similar levels of mitogenic activity for foreskin fibroblasts as compared to normal control sera. These differences may be due to the source of fibroblasts; however, our data were consistent with lower mitogenic activity in scleroderma serum regardless of the source of fibroblasts.
The role of PDGF in connective tissue formation, fibrosis, or wound repair has been studied for years. 1 " 3 ' P DGF has been found to be the principal mitogenic factor for fibroblasts, smooth muscle cells, and fibroblastic cell lines, 1 " 3 and chemoattractant for vascular smooth muscle cells and fibroblasts. 6^ Addition of PDGF to a model wound system stimulated the formation of connective tissue in vivo. 27 Thus PDGF appears to play an important role in connective tissue formation. The present study showed that most of the mitogenic activity in human serum for fibroblasts was PDGF-related activity, and this activity could be decreased by 78% by taking 300 mg per day of dipyridamole for 3 days. Apparently, dipyridamole caused this by blocking platelet aggregation and PDGF release from platelets without changing the total mitogenic activities in the platelets. The most surprising observation is that this occurred when blood underwent maximal clotting as in the serum collection tubes. These data suggest that the effects of dipyridamole on the progression of vascular diseases needs to be carefully evaluated. Additionally, it is our hope that dipyridamole treatment may be applied to animal models of fibrosis and wound healing enabling the further investigation of the role of platelets and plateletderived factors in these processes in vivo.
